Can platinib effectively extend the patient's life?

Pralsetinib is a kinase inhibitor that targets RET fusion rearrangements and is mainly used to treat patients with non-small cell lung cancer (NSCLC) and thyroid cancer carrying RET fusion mutations. It effectively blocks the proliferation and metastasis of cancer cells by precisely inhibiting the RET signaling pathway. It is one of the representative drugs in the field of precision medicine.

According to the current clinical application trend, platinib can indeed significantly delay the progression of the disease and prolong the overall survival (OS) of patients to a certain extent, especially in patients whose standard treatment regimen is unsatisfactory. At the same time, it has shown the potential for sustained benefit in terms of clinical response rate and progression-free survival (PFS).

RET fusion-positive tumors themselves are a type of driver mutation, which means that as long as targeted therapy is properly targeted, the curative effect is often rapid and durable. The emergence of platinib gives these patients the opportunity to control their disease in the long term. Especially among patients who have not received previous systemic treatment, their tumors respond faster and their disease remains stable longer after taking the drug, which is conducive to improving the quality of life and prolonging survival. Compared with traditional chemotherapy, its side effects are milder, reducing the risk of treatment interruption and improving the feasibility of long-term medication.

However,"Extending life" cannot simply be understood as "curing", but should be regarded as delaying the progression of the disease by controlling tumor progression, alleviating symptoms, and mitigating complications. Since each patient's genetic characteristics, physical status, and comorbid diseases are different, the effect of Platinib will also vary among individuals. Some patients may experience significant response early in treatment, while others may have a weaker response due to tumor heterogeneity or changes in the microenvironment. Therefore, during the use of platinib, doctors usually combine imaging examinations, tumor markers and symptom improvement to comprehensively evaluate the efficacy to ensure that treatment adjustments are made at the optimal time.

Reference: https://gavreto.com/